CloudScientific Partners with MindRank to Accelerate AI-Powered ADME/T Platform for Drug Discovery

Nov 13, 2024 19:16 CST Updated 19:16

MindRank

AI Drug Developer

November 13, 2024, Shanghai, China

Recently, Shanghai Kangyusheng Information Technology Co., Ltd. ("Kangyusheng") and clinical-stage AI-driven innovative drug R&D company MindRank Ltd. (MindRank) officially signed a distribution cooperation agreement.Both parties will jointly promote MindRank's self-developed ADME/T (Absorption, Distribution, Metabolism, Excretion/Toxicity) property prediction platform, ADMET Ranker.^TMApplication and Promotion in ChinaThis collaboration will provide pharmaceutical research and development enterprises, academic institutions, and research teams with more efficient and precise drug property prediction solutions, accelerating new drug development and improving overall success rates.

MindRank's Self-Developed ADMET Ranker Based on Machine Learning/Deep Learning^TMThe platform, relying on tens of millions of high-quality data that have undergone rigorous verification and top-tier self-developed large-scale artificial intelligence model algorithms, has demonstrated its exceptional accuracy and reliability in collaborations with multiple listed companies and in self-developed drugs. The platform integrates the world's largest single-property ADME/T dataset through its self-developed large model data mining system, comprehensively covering hundreds of key ADME/T properties of small molecule compounds, and has achieved outstanding performance in various drug-likeness prediction fields. The platform also provides comprehensive user support, including continuous data updates and model optimization, offering precise scientific decision-making support to researchers at an early stage and significantly reducing risks in subsequent experiments and clinical development. In evaluations using private data from several listed companies, the platform has shown significantly better performance than many international commercial software solutions.

Shanghai Kangyusheng Information Technology Co., Ltd., one of the leading suppliers of informatization solutions for life sciences and drug research and development in China, boasts profound industry experience and extensive customer resources. Through this collaboration, Kangyusheng will leverage its rich experience in the Chinese market to support MindRank’s ADMET Ranker via market promotion, technical support, and customer service.^TMThe platform's implementation and popularization in the Chinese market. Shanghai Kangyusheng Information Technology Co., Ltd. will provide customers with a series of marketing activities, including product introduction meetings, technical seminars, and online training courses to help Chinese researchers quickly master ADMET Ranker.^TMThe method of using the platform to achieve more precise drug research and development.

Zhangming Niu, Founder and CEO of MindRank

"We are very pleased to reach this cooperation with Kangyusheng. With Kangyusheng's extensive experience in life science informatization and drug discovery support, we look forward to the wider application of MindRank’s AI+ADME/T prediction platform in China, empowering the new drug development industry and helping better drugs benefit the public more quickly."

Lin JianchengShanghai Kangyusheng Information Technology Co., Ltd.CEO

“Shanghai Kangyusheng Information Technology Co., Ltd. is very pleased to collaborate with MindRank on the AI+ADME/T prediction platform. ADMET property prediction plays a crucial role in obtaining better drug candidates. Using larger-scale and high-quality data, MindRank has developed validated, high-quality ADME/T prediction models through AI methods, which will benefit our extensive customer base in innovative drug research and development. We hope to jointly contribute to the rapid development of China's pharmaceutical industry!”

ADMET Ranker^TMProvide trials through various methods including online, local, and MOE extension interfaces. If you are interested, please feel free to contact:

marketing@cloudscientific.com

About MindRank

MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high clinical value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug research and development, thereby helping more lives regain health.

The AI pharmaceutical solution of the company was once rated by the authoritative European and American institution Deep Pharma Intelligence as "one of the 11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020." In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Enterprise List as "China's Most Socially Impactful Startup Company."

About Shanghai Kangyusheng Information Technology Co., Ltd.

Shanghai Kangyusheng Information Technology Co., Ltd. is a company specializing in providing comprehensive scientific information solutions for the biopharmaceutical field. The company is committed to enhancing your R&D capabilities, accelerating your R&D progress, and increasing your value through advanced scientific information technology and services, helping your research stay at the forefront of the world in a cost-effective manner. The company currently serves over 1,200 enterprises and academic clients in China's biopharmaceutical industry, sincerely providing them with strong scientific information software technology products and service support for their R&D innovation!